Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Clinical trial assessing safety and efficacy of paxalisib in combination with KEYTRUDA® (pembrolizumab) or LYNPARZA® (olaparib) in women with triple negative breast cancer.

Next Previous
Trial Profile

Phase 1 Clinical trial assessing safety and efficacy of paxalisib in combination with KEYTRUDA® (pembrolizumab) or LYNPARZA® (olaparib) in women with triple negative breast cancer.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paxalisib (Primary) ; Carboplatin; Gemcitabine; Olaparib; Paclitaxel; Pembrolizumab
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Adverse reactions
  • Acronyms ABC-Pax

Most Recent Events

  • 26 May 2026 According to Kazia therapeutics media release, . The expanded dataset is expected to provide a more meaningful assessment of objective response rate ("ORR"), progression-free survival ("PFS") and translational biomarkers. Additional clinical trial updates are anticipated throughout 2026 and into 2027 and , planned enrollment has increased from 12 to 36 patients.
  • 27 Jan 2026 Results published in the Media Release
  • 09 Jan 2026 According to Kazia therapeutics media release, the company expects to provide a clinical and translational update before the end of the month from its ongoing Phase 1b trial evaluating paxalisib in advanced triple-negative breast cancer (TNBC).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top